

Global Code of Conduct - Amendments

Following is a description of amendments to the Global Code of Conduct (the “*Code*”) of Ultragenyx Pharmaceutical Inc. (the “*Company*”) adopted within the last 12 months.

October 30, 2018 Amendments

On October 30, 2018, the Company’s Audit Committee amended and restated the Code to:

- ensure that the content is presented in a user-friendly format that is easy to understand;
- add and update policies addressing areas of compliance that are important for a commercial organization;
- add policies addressing antitrust and competition laws, money laundering, trade restrictions, transparency, patient and caregiver interactions, patient organization interactions, interactions with healthcare professionals, accurate business records, scientific publications, and the Company’s compliance program and philosophy;
- revise or supplement existing policies, including incorporating General Data Protection Regulation principles, addressing GxP and drug safety requirements with greater specificity, and clarifying expectations concerning gifts, interactions with government officials, and social media use by employees;
- expand the scope and purpose of the former whistleblower hotline to a more comprehensive Compliance Hotline;
- remove dated, duplicative or unnecessary language; and
- provide additional resources for questions.

The amendment and restatement of the Code took effect upon adoption by the Company’s Audit Committee and did not result in any waiver, explicit or implicit, of any provision of the Company’s Code of Business Conduct and Ethics previously in effect. The Code was renamed as part of the amendments made by the Company’s Audit Committee.

The Code can be reviewed at www.ultragenyx.com in the “Corporate Governance” subsection of the “Investors” tab.